In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SPACs Surge In 2020

Special Purpose Acquisition Companies Target Biopharma And Medtech: Infographic

Executive Summary

Despite the COVID-19 chaos felt by many industries in 2020, biopharma IPOs recorded a banner year – including a marked rise in the use of special purpose acquisition companies (SPACs), also known as blank check companies. 

You may also be interested in...



Are SPACs Good Or Bad For Biopharma?

Special Purpose Acquisition Companies (SPACs) homed in on the biopharma industry in 2020, providing biotech companies with a faster and looser route to the public market. Is there a downside?

Carving Out New Spaces In Cancer Immunotherapy

With a combined $335m raised in a crossover series B funding and an IPO last summer, Cambridge, MA-based iTeos Therapeutics has the juice to move its two cancer immunotherapy clinical programs forward.

The Benefit In B Corps

Privately held Chiesi Farmaceutica, a global health care and biopharmaceuticals firm headquartered in Italy, became a certified B Corporation in 2019. The B Corp impact assessment framework helped Chiesi demonstrate its mission of becoming a “double purpose” business, one that executes on business objectives but also works to protect the environment and promote social justice. Will other companies follow suit?

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel